Back to top

Analyst Blog

The US Food and Drug Administration (FDA) recently extended the Prescription Drug User Fee Act (PDUFA) date for Impax Laboratories, Inc.’s (IPXL - Snapshot Report) New Drug Application (NDA) for Rytary (IPX066). The US regulatory body will now announce its decision by January 21, 2013 instead of October 21, 2012. Importantly, the agency did not ask the company to conduct new studies.

IPX066 is being developed for the treatment of patients suffering from idiopathic Parkinson’s disease. In September this year, Impax had submitted the information on an excipient in IPX066 formulation as requested by the FDA. As the submission of the additional information was within three months of October 21, 2012, the US regulatory body extended the decision date to review the information.

We remind investors that in December 2010, Impax entered into a license, development and commercialization agreement with GlaxoSmithKline plc (GSK - Analyst Report) for IPX066. As per the terms of the agreement, Glaxo is responsible for the development and commercialization of the candidate outside the US and Taiwan.

The company has already announced results from pivotal phase III studies of IPX066. The studies include APEX-PD (early PD), ADVANCE-PD (advanced PD) and ASCEND-PD (advanced PD).

Currently, the Parkinson’s disease market has players like Novartis AG (NVS - Snapshot Report) and Teva Pharmaceutical Industries Limited (TEVA - Analyst Report).

Apart from its lead pipeline candidate IPX066, Impax is also developing IPX159 for the treatment of Restless Legs Syndrome (RLS). The company is currently conducting a phase IIb study of IPX159, results of which is expected in mid-2013.

Our Recommendation

We currently have a Neutral recommendation on Impax. The stock carries a Zacks #3 Rank (short-term ‘Hold’ rating).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
QIHOO 360 T… QIHU 95.04 +4.95%
PILGRIM'S P… PPC 31.52 +3.72%
CLAYTON WIL… CWEI 138.97 +3.55%
CALLON PETE… CPE 11.50 +3.14%
ACTELION LT… ALIOF 124.80 +2.97%